Skip to main content

Table 1 Demographic and clinical variables, mean (standard deviation)

From: EEG alpha reactivity and cholinergic system integrity in Lewy body dementia and Alzheimer’s disease

 HC (N = 40)AD (N = 21)LBD (N = 41)Group differences
Male to female25:1514:735:6χ2 = 5.8, p = 0.06a
Age73.4 (6.6)74.7 (7.2)74.6 (6.5)F(2, 99) = 0.4, p = 0.66b
AChEI2035χ2 = 1.4, p = 0.25c
PD meds028χ2 = 26.2, p < 0.001c
Duration4.1 (2.4)f3.2 (2.1)gU = 270, p = 0.07d
MMSE28.8 (1.1)21.6 (3.7)23.1 (3.8)t60 = 1.5, p = 0.15e
UPDRS III3.9 (4.2)1.7 (1.5)20.2 (8.6)t60 = 9.7, p < 0.001e
CAF total0.3 (0.7)h5.2 (4.3)jt56 = 5.1, p < 0.001e
Mayo total9.4 (4.4)h14.3 (5.5)jt56 = 3.5, p = 0.001e
Mayo cogn2.0 (1.9)h3.0 (1.8)jt56 = 2.0, p = 0.05e
NPI total7.4 (7.2)h14.5 (10.5)gt58 = 2.7, p = 0.009e
NPI hall0.05 (0.2)h2.0 (2.0)gt58 = 4.5, p < 0.001e
  1. AChEI number of patients taking acetylcholinesterase inhibitors, AD Alzheimer’s disease, CAF total Clinician Assessment of Fluctuation total score, Duration duration of cognitive symptoms in years, HC healthy controls, LBD Lewy body dementia, Mayo total Mayo Fluctuation Scale, Mayo cognitive Mayo Fluctuation cognitive subscale, MMSE Mini-Mental State Examination, PD meds number of patients taking dopaminergic medication for the management of Parkinson’s disease symptoms, UPDRS III Unified Parkinson’s Disease Rating Scale III (motor subsection), NPI Neuropsychiatric Inventory, NPI hall NPI hallucination subscore
  2. aChi-square test HC, AD, LBD
  3. bOne-way ANOVA HC, AD, LBD
  4. cChi-square test AD, LBD
  5. dMann-Whitney U test AD, LBD
  6. eStudent’s t test AD, LBD
  7. fN = 19
  8. gN = 40
  9. hN = 20
  10. jN = 38